Clopidogrel Krka

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clopidogrel (as hydrochloride)

Available from:

Krka, d.d., Novo mesto

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Peripheral Vascular Diseases; Stroke; Myocardial Infarction

Therapeutic indications:

Clopidogrel je navedeno pri odraslih za preprečevanje atherothrombotic dogodkov v:Bolnike, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni.

Product summary:

Revision: 19

Authorization status:

Pooblaščeni

Authorization date:

2009-09-23

Patient Information leaflet

                                30
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago
in svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto,
Slovenija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
7 filmsko obloženih tablet: EU/1/09/556/001
14 filmsko obloženih tablet: EU/1/09/556/002
28 filmsko obloženih tablet: EU/1/09/556/003
30 filmsko obloženih tablet: EU/1/09/556/004
50 filmsko obloženih tablet: EU/1/09/556/005
56 filmsko obloženih tablet: EU/1/09/556/006
60 filmsko obloženih tablet: EU/1/09/556/010
84 filmsko obloženih tablet: EU/1/09/556/007
90 filmsko obloženih tablet: EU/1/09/556/008
100 filmsko obloženih tablet: EU/1/09/556/009
112 filmsko obloženih tablet: EU/1/09/556/012
120 filmsko obloženih tablet: EU/1/09/556/011
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Klopidogrel Krka 75 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
n
31
PC
SN
NN
32
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Klopidogrel Krka 75 mg filmsko obložene tablete
klopidogrel
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
KRKA
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
33
B. NAVODILO ZA UPORABO
34
NAVODILO ZA UPORABO
KLOPIDOGREL KRKA 75 MG FILMSKO OBLOŽENE TABLETE
klopidogrel
PRED ZAČETKOM JEMANJA ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Njim bi lahko celo
škodova
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Klopidogrel Krka 75 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki
klopidogrelijevega klorida.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Rožnate, okrogle in rahlo izbočene filmsko obložene tablete.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
_Sekundarno preprečevanje aterotrombotičnih dogodkov_
Klopidogrel je indiciran pri:
-
odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35
dni), ishemično
možgansko kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano
periferno arterijsko boleznijo.
-
odraslih bolnikih z akutnim koronarnim sindromom:
-
akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina
ali miokardni
infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen
stent po perkutani
koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA
– acetylsalicylic acid).
-
akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA
pri bolnikih, pri
katerih se izvaja perkutana koronarna intervencija (vključno z
bolniki, katerim je bila
vstavljena opornica), ali pri bolnikih, ki se zdravijo z zdravili in
so primerni za
trombolitično/fibrinolitično zdravljenje.
_Pri bolnikih z zmernim do zelo tveganim prehodnim ishemičnim napadom
(TIA - Transient Ischemic _
_Attack) ali manjšo ishemično možgansko kapjo (IMK)_
Klopidogrel je v kombinaciji z ASA indiciran pri:
-
odraslih bolnikih z zmernim do zelo tveganim TIA (ocena ABCD2
1
≥ 4) ali manjšo IMK (ocena
NIHSS
2
≤ 3) v 24 urah po TIA ali IMK.
_Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri
atrijski fibrilaciji_
Pri odraslih bolnikih z atrijsko fibrilacijo, ki imajo vsaj en
dejavnik tveganja za žilne dogodke in ki
niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo
majhno tveganje za krvavitev,
je klopidogrel v kombinaciji z ASA indiciran za
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-12-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-12-2023
Public Assessment Report Public Assessment Report Bulgarian 13-09-2017
Patient Information leaflet Patient Information leaflet Spanish 04-12-2023
Public Assessment Report Public Assessment Report Spanish 13-09-2017
Patient Information leaflet Patient Information leaflet Czech 04-12-2023
Public Assessment Report Public Assessment Report Czech 13-09-2017
Patient Information leaflet Patient Information leaflet Danish 04-12-2023
Public Assessment Report Public Assessment Report Danish 13-09-2017
Patient Information leaflet Patient Information leaflet German 04-12-2023
Public Assessment Report Public Assessment Report German 13-09-2017
Patient Information leaflet Patient Information leaflet Estonian 04-12-2023
Public Assessment Report Public Assessment Report Estonian 13-09-2017
Patient Information leaflet Patient Information leaflet Greek 04-12-2023
Public Assessment Report Public Assessment Report Greek 13-09-2017
Patient Information leaflet Patient Information leaflet English 04-12-2023
Public Assessment Report Public Assessment Report English 13-09-2017
Patient Information leaflet Patient Information leaflet French 04-12-2023
Public Assessment Report Public Assessment Report French 13-09-2017
Patient Information leaflet Patient Information leaflet Italian 04-12-2023
Public Assessment Report Public Assessment Report Italian 13-09-2017
Patient Information leaflet Patient Information leaflet Latvian 04-12-2023
Public Assessment Report Public Assessment Report Latvian 13-09-2017
Patient Information leaflet Patient Information leaflet Lithuanian 04-12-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-12-2023
Public Assessment Report Public Assessment Report Lithuanian 13-09-2017
Patient Information leaflet Patient Information leaflet Hungarian 04-12-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 04-12-2023
Public Assessment Report Public Assessment Report Hungarian 13-09-2017
Patient Information leaflet Patient Information leaflet Maltese 04-12-2023
Public Assessment Report Public Assessment Report Maltese 13-09-2017
Patient Information leaflet Patient Information leaflet Dutch 04-12-2023
Public Assessment Report Public Assessment Report Dutch 13-09-2017
Patient Information leaflet Patient Information leaflet Polish 04-12-2023
Public Assessment Report Public Assessment Report Polish 13-09-2017
Patient Information leaflet Patient Information leaflet Portuguese 04-12-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 04-12-2023
Public Assessment Report Public Assessment Report Portuguese 13-09-2017
Patient Information leaflet Patient Information leaflet Romanian 04-12-2023
Public Assessment Report Public Assessment Report Romanian 13-09-2017
Patient Information leaflet Patient Information leaflet Slovak 04-12-2023
Public Assessment Report Public Assessment Report Slovak 13-09-2017
Patient Information leaflet Patient Information leaflet Finnish 04-12-2023
Public Assessment Report Public Assessment Report Finnish 13-09-2017
Patient Information leaflet Patient Information leaflet Swedish 04-12-2023
Public Assessment Report Public Assessment Report Swedish 13-09-2017
Patient Information leaflet Patient Information leaflet Norwegian 04-12-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 04-12-2023
Patient Information leaflet Patient Information leaflet Icelandic 04-12-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 04-12-2023
Patient Information leaflet Patient Information leaflet Croatian 04-12-2023
Public Assessment Report Public Assessment Report Croatian 13-09-2017

Search alerts related to this product